Earnings Summary

Turning Point Therapeutics Inc’s revenue fell -98.3% since last year same period to $0.43Mn in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 1602.04% jump in its revenue since last 3-months.

Turning Point Therapeutics Inc’s net profit fell -109.68% since last year same period to $-74.44Mn in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 5.1% jump in its net profits since last 3-months.

Turning Point Therapeutics Inc’s net profit margin fell -12219.35% since last year same period to -17353.15% in the Q1 2022. On a quarterly growth basis, Turning Point Therapeutics Inc has generated 94.42% jump in its net profit margins since last 3-months.

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.7 - a -12.58% fall from last quarter’s estimates.

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.7.

Turning Point Therapeutics Inc’s earning per share (EPS) fell -105.48% since last year same period to -1.5 in the Q1 2022. This indicates that the Turning Point Therapeutics Inc has generated -105.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Turning Point Therapeutics Inc’s return on assets (ROA) stands at -0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Turning Point Therapeutics Inc’s return on equity (ROE) stands at -0.23.